P53 has an important role in the processing of starvation signals. P53-dependent molecular mediators of the Warburg effect reduce glucose consumption and promote mitochondrial function. We therefore hypothesized that the retention of wild-type p53 characteristic of primary glioblastomas limits metabolic demands induced by deregulated signal transduction in the presence of hypoxia and nutrient depletion. Here we report that short hairpin RNA-mediated gene suppression of wild-type p53 or ectopic expression of mutant temperature-sensitive dominant-negative p53 V135A increased glucose consumption and lactate production, decreased oxygen consumption and enhanced hypoxia-induced cell death in p53 wild-type human glioblastoma cells. Similarly, genetic knockout of p53 in HCT116 colon carcinoma cells resulted in reduced respiration and hypersensitivity towards hypoxia-induced cell death. Further, wild-type p53 gene silencing reduced the expression of synthesis of cytochrome c oxidase 2 (SCO2), an effector necessary for respiratory chain function. An SCO2 transgene reverted the metabolic phenotype and restored resistance towards hypoxia in p53-depleted and p53 mutant glioma cells in a rotenonesensitive manner, demonstrating that this effect was dependent on intact oxidative phosphorylation. Supplementation with methyl-pyruvate, a mitochondrial substrate, rescued p53 wild-type but not p53 mutant cells from hypoxic cell death, demonstrating a p53-mediated selective aptitude to metabolize mitochondrial substrates. Further, SCO2 gene silencing in p53 wild-type glioma cells sensitized these cells towards hypoxia. Finally, lentiviral gene suppression of SCO2 significantly enhanced tumor necrosis in a subcutaneous HCT116 xenograft tumor model, compatible with impaired energy metabolism in these cells. These findings demonstrate that glioma and colon cancer cells with p53 wild-type status can skew the Warburg effect and thereby reduce their vulnerability towards tumor hypoxia in an SCO2-dependent manner. Targeting SCO2 may therefore represent a valuable strategy to enhance sensitivity towards hypoxia and may complement strategies targeting glucose metabolism.
Introduction
Alteration of metabolism in tumor cells is increasingly recognized as a core component of the neoplastic phenotype that complements the classical hallmarks of cancer (Hanahan and Weinberg, 2000; Gottlieb, 2009) . Otto Warburg in the early 1920s defined the phenomenon of aerobic glycolysis (Warburg, 1956a, b) characteristic of cancer cells preferentially utilizing the glycolytic pathway in the presence of oxygen, although less ATP per mole glucose is produced by glycolysis than by mitochondrial respiration. It has become evident, however, that increased glycolysis can be advantageous for tumors cells in many ways (Gatenby and Gillies, 2004; Kondoh et al., 2005; Moreno-Sanchez et al., 2007; DeBerardinis et al., 2008) . First, as long as sufficient glucose is available, energy demand can be satisfied by enhanced glycolytic activity, because the glycolytic flux involves fewer biochemical reactions than cellular respiration (Curi et al., 1988; Guppy et al., 1993; Gatenby and Gillies, 2004) . In addition, glycolysis provides cells with intermediate products needed for biosynthetic pathways, including riboses for nucleotide setup and glycerate or citrate for lipid synthesis. Furthermore, the pentose phosphate pathway generates NADPH, acting as energy source and reducing agent for protection against reactive oxygen species (ROS). Several aspects of the molecular mechanisms underlying the glycolytic phenotype have recently been elucidated. Signaling downstream of receptor tyrosine kinases influences glucose metabolism. In particular, the phosphatidylinositol-3 kinase/protein kinase B/Akt pathway that is activated in the vast majority of primary glioblastomas (Choe et al., 2003) increases glycolytic activity by the upregulation of glucose transporter 1 (Barnes et al., 2002) and phosphorylation of hexokinase-II (Miyamoto et al., 2008) .
Another event important for the development of cancer is the inactivation of the tumor suppressor p53 (Vogelstein et al., 2000) . Depending on the cellular conditions, p53 suppresses tumorigenesis by multiple mechanisms, including cell cycle regulation, initiation of DNA repair, induction of apoptosis, activation of autophagy or protection from autophagy-induced cell death and regulation of ROS production. Recently, however, p53 has been demonstrated to act also as a potent metabolic regulator. The p53-dependent metabolic response is driven by the starvation-sensitive AMP-activated protein kinase (AMPK) pathway (Jones et al., 2005) . At least two effectors downstream of p53 have been identified. First, p53 maintains mitochondrial respiration by inducing synthesis of cytochrome c oxidase 2 (SCO2) (Matoba et al., 2006) . SCO2 is essential for the proper assembly of cytochrome c oxidase, which catalyzes the transfer of reducing equivalents from cytochrome c to molecular oxygen in the inner mitochondrial membrane. Loss of p53 or SCO2 results in a shift of metabolism towards glycolysis (Corcoran et al., 2006; Matoba et al., 2006; Ma et al., 2007) . In addition, p53 may suppress glycolysis and increase the activity of the pentose phosphate shunt via induction of tp53 inducer and regulator of glycolysis (TIGAR) (Bensaad et al., 2006) .
Glioblastomas are among the most hypoxic human tumors, and primary glioblastomas, in particular, feature extensive necrosis. It is intriguing that almost all these tumors retain wild-type p53 status in contrast to secondary glioblastomas arising from low-grade gliomas, in which mutation of p53 is frequent (Watanabe et al., 1996; Tohma et al., 1998) . We therefore hypothesized that wild-type p53 in glioma cells limits metabolic demands induced by deregulated signal-transduction processes in the presence of hypoxia and nutrient depletion, and thereby enhances viability under the adverse conditions of the glioblastoma microenvironment.
We here report that antagonism of p53 enhances the glycolytic phenotype and promotes hypoxia-induced cell death in an SCO2-dependent manner. SCO2 gene silencing mimicks the effects of p53 suppression in vitro, while overexpression of SCO2 in cells with inactivated p53 confers the phenotype of p53 wild-type cells.
Results

Antagonizing p53 enhances hypoxia-induced cell death
To analyze the importance of p53 for the ability of glioma cells to survive hypoxic stress, three models of p53 inactivation were used: (i) LNT-229 glioma cells stably transfected with a short-hairpin RNA targeting p53 (p53sh); (ii) LNT-229 cells in which the p53 transactivation activity was inhibited by stable expression of the temperature-sensitive dominant-negative p53 V135A mutant (Naumann et al., 1998) ; and (iii) HCT116 human colon carcinoma cells carrying a targeted deletion of p53 achieved by homologous recombination (p53
) and appropriate control cells (Ryan et al., 1993; Bunz et al., 1998) . In a first step, we analyzed the expression of p53 in tumor cells exposed to limited glucose availability (2 mM) and different oxygen concentrations (21, 1 or 0.1% O 2 ) ( Figure 1a ). Hypoxia had no consistent effect on p53 protein levels. P53 protein levels in LNT-229 cells stably transfected with the p53sh sequence (LNT-229 p53sh cells) were efficiently reduced under all conditions. In LNT-229 temperature-sensitive p53 (p53ts) cells, the murine transgenic p53 was detectable in addition to the endogenous human p53. Again, hypoxia had no effect on endogenous (p53sc263 antibody) or on transgenic (p53Ab4 antibody) p53 protein levels. No p53 was detectable in HCT116 p53 À/À cells. As conflicting results concerning transcriptional activity of p53 under hypoxia exist (Liu et al., 2007; Zhao et al., 2009) , p53 transactivation activity under the experimental conditions was analyzed by luciferase assay. The p53-transactivation capacity was significantly reduced in p53-depleted cells (LNT-229 p53sh, LNT-229 p53ts and HCT116 p53 À/À ) at all experimental conditions (Figure 1b) . Furthermore, hypoxia per se did not significantly alter the p53 transactivation activity. These results demonstrate that the expression of p53 and its transactivation activity are retained under starving conditions of hypoxia and glucose deprivation. To test whether suppression of p53 modulates the sensitivity towards hypoxia-induced cell death, LNT-229 puromycin (puro)/p53sh, LNT-229 hygromycin (hygro)/p53ts and HCT116 p53
À/À cells were exposed to glucose restriction (2 mM) and different oxygen concentrations (21, 1 or 0.1% O 2 ) for 24 h, and cell death was assessed by propidium iodide (PI) staining. In all three paradigms, the inactivation of p53 sensitized the cells towards hypoxia-induced cell death (Figure 1c ), an effect that was most prominent at moderate hypoxia.
P53 is a regulator of glucose consumption in tumor cells As p53 plays a regulatory role in glucose metabolism during stress situations (Kondoh et al., 2005; Bensaad et al., 2006; Corcoran et al., 2006; Matoba et al., 2006) , we hypothesized that suppression of wild-type p53 resulted in a higher nutrient demand under starvation conditions. This would accelerate nutrient depletion and promote earlier cell death. We compared glucose consumption and lactate production in LNT-229 puro/ p53sh or HCT p53
À/À cells in normoxia (21% O 2 ) and hypoxia (1 or 0.1% O 2 ). P53-depleted cells showed an increased glucose consumption and lactate production under all conditions tested independent of oxygen supply (Figures 2a-d) . Similar results were obtained with LNT-229 hygro/p53ts cells (data not shown). Therefore, p53 deletion leads to an increased glucose consumption and consequently to an accelerated glucose depletion.
Inhibiting p53 function represses cellular respiration
Recent work has elucidated that p53 enhances cellular respiration through transcriptional upregulation of SCO2, which is essential for the assembly of cytochrome c oxidase and thus maintains oxidative phosphorylation (Matoba et al., 2006) . As p53-antagonized cells were more sensitive towards hypoxia, we hypothesized that this was elicited by regulation of SCO2. We therefore determined SCO2 expression by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis in these cell lines. Antagonizing p53 repressed SCO2 in glioma and colon carcinoma cells (Figure 3a) . To assess the functional consequences of p53 deletion on cellular respiration, oxygen consumption was directly measured in p53-suppressed and control cell lines. As shown in Figure 3b , loss of p53 wild-type activity led to a considerable reduction in oxygen consumption, confirming a regulatory function of p53 for cellular respiratory activity.
SCO2 is a p53 effector that maintains respiration and reduces sensitivity towards hypoxic stress To characterize the role of SCO2 as an effector of p53, an SCO2 expression vector was transfected into LNT-229, LNT-229 p53sh or T98G (p53 mutant) cells. In addition, expression of SCO2 was transiently suppressed by small interfering RNA (siRNA) in parental LNT-229 cells (Figure 4a ). Overexpression of SCO2 enhanced oxygen A functional respiratory chain is required for the SCO2-mediated protection To determine whether the effect of SCO2 on hypoxiainduced cell death depends on its function related to the mitochondrial respiratory chain, SCO2-transfected LNT-229 p53sh cells were exposed to moderate hypoxia (1% O 2 ) in the presence or absence of rotenone, an inhibitor of complex I of the respiratory chain. Rotenone profoundly repressed oxygen consumption in LNT-229 p53sh cells transfected with either control vector or SCO2 (Figure 5a ). Hypoxia-induced cell death Figure 2) . As SCO2 still had protective effects even in the presence of the complex I inhibitor rotenone, additional mechanisms independent of SCO2's function in oxidative phosphorylation might exist. Because SCO2 has recently been shown to suppress ROS levels (Sung et al., 2010) , we investigated whether ROS levels would be modulated by SCO2 under starvation conditions, too. Indeed, intracellular ROS concentrations were reduced by ectopic expression of SCO2 (Supplementary Figure 3) , supporting a role for SCO2 in decreasing ROS levels.
Suppression of SCO2 does not impact on clonogenicity in vitro
To analyze if p53 or SCO2 modulate clonogenicity of colon cancer cells in vitro under physiological conditions (3% O 2 and 5.5 mM glucose), anchorage-independent growth was assessed by soft agar colony formation assays. To study in detail the role of SCO2, HCT116 p53 þ / þ cells were stably transfected with an shRNA targeting SCO2 (SCO2 sh) via a lentiviral system, resulting in about 75% knockdown in RT-PCR analysis (data not shown). Knockout of p53 significantly impaired the ability of anchorage-independent growth, whereas no such effect was observable in the SCO2-suppressed cells (Figure 6 ). These results indicate that SCO2 does not impair clonogenic capacity per se in the presence of sufficient nutrients.
Depletion of SCO2 promotes necrosis formation As our in vitro models might not appropriately reflect the metabolic environment of tumor cells in vivo, we further analyzed the growth of HCT116 p53 , mean±s.d., P40.05) in accordance with previous reports using similar cell numbers (Bhonde et al., 2006; Buzzai et al., 2007; Yoon et al., 2009) . Similarly, SCO2-suppressed tumors did not have significant altered doubling times compared with control tumors (6.3 ± 1.52 vs 5.3 ± 0.5 d), but the tumor volumes at the end of the experiment were slightly larger in SCO2-depleted tumors (volumes at day 31 of scrambled sh vs SCO2 sh tumors: 1293 ± 350 vs 1815 ± 641 mm 3 , mean ± s.d., Po0.05; Figure 7b ). Because faster glucose depletion of SCO2-suppressed tumor cells in vitro (Figure 2 and data not shown) might be expected to result in altered necrosis formation in vivo, the extent of necrosis in comparison to the total tumor area was determined. Whereas in control tumors, necrosis had a patchy distribution pattern with islets of viable tumors within necrotic areas, SCO2-suppressed tumors indeed revealed extensive central necrosis without viable tumors cells. Further, when the proportion of necrosis compared with the total tumor area was quantitatively analyzed, SCO2-suppressed tumors were characterized by significantly more necrosis compared with control tumors (Figure 7c ). , 2005) . Second, the p53 target TIGAR inhibits glycolysis and increases metabolism in the pentose phosphate shunt (Bensaad et al., 2006) . Third, SCO2 has been shown to be a p53 target gene (Matoba et al., 2006) important for the assembly of the cytochrome c oxidase subunit within the inner mitochondrial membrane, thereby promoting cellular respiration (Leary et al., 2004 (Leary et al., , 2009 ). In summary, p53 serves as a key metabolic regulator limiting glucose consumption and increasing energy efficacy. In primary glioblastoma, despite its cell cycle-regulating and proapoptotic functions, p53 is retained in its wild-type state in almost all cases (Fults et al., 1992; Ohgaki and Kleihues, 2007) . In contrast, the receptor tyrosine kinase pathway is typically activated in these tumors, leading to increased cellular metabolic demand and glucose consumption. Therefore, we hypothesized that the retention of wildtype p53 serves to adjust glucose metabolism to enable survival under the starvation conditions characteristic of the tumor microenvironment.
SCO2 inhibits hypoxia-induced cell death
We report here that, indeed, under hypoxia, inactivation of p53 increased glucose consumption and cell death. Expression of SCO2 was downregulated and oxygen consumption was suppressed by antagonism of p53 (Figure 3) , consistent with the observation that SCO2 is regulated by p53 (Matoba et al., 2006) . Transfection of SCO2 into p53-deficient cells reestablished the metabolic phenotype of p53 wild-type cells enabling cellular respiration and enhancing cellular survival (Figure 4 ). Most likely, this is due to the better efficiency of mitochondrial respiration compared with glycolysis, with 36 mol of ATP generated by oxidative phosphorylation vs 2 mol generated in the glycolytic pathway. Excess glucose rescued hypoxiainduced cell death in glycolytic (p53 mutant) as well as oxidative (p53 wild-type or SCO2-transfected) cells (Figure 5c ), supporting the assumption that energy depletion is causal for the loss of viability under hypoxia and that glucose can be metabolized irrespective of p53 status under these conditions. Supplementation with methyl-pyruvate rescued survival only in p53 wild-type cells, but not in p53 mutant cells (Figure 5d ). This is indicative of a functional p53-dependent respiration and of a selective aptitude of p53 wild-type cells compared with p53 mutant cells to metabolize mitochondrial substrates. P53 wild-type and SCO2-restored cells indeed maintained higher ATP levels under stress conditions than p53 mutant cells (Supplementary Figure 1) . However, although an increase in the phosphorylation level of the energy-sensing kinase AMPKa and subsequent modulation of its downstream targets acetyl coA carboxylase or 4E binding protein 1 were detectable under hypoxic conditions, these adaptive responses were independent of the SCO2 expression (Supplementary Figure 2) . Therefore, during hypoxia and glucose depletion, AMPK is activated irrespective of SCO2 status. We hypothesize that AMPK then triggers a starvation response that is more efficient in p53 wild-type or SCO2-expressing cells because these are able to utilize energy-effective oxidative phosphorylation, while p53 mutant or SCO2-deficient cells deplete their glucose stores more rapidly (summarized in Figure 8 , see also Figure 2 ). The ensuing profound ATP depletion resulting in cell demise is possibly too rapid to regulate, in turn, phospho-AMPK to higher levels in p53 mutant/ SCO2-deficient cells. 
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As SCO2 expression did not decrease cell death under profound hypoxia, SCO2 seems to specifically act as a hypoxia-protective protein in the presence of at least traces of oxygen. Furthermore, the assumption that SCO2-mediated protection from hypoxia-induced cell death is related to its function at the mitochondrial respiratory chain and requires an intact oxidative phosphorylation is supported by the observation that the protective effect of SCO2 is attenuated by inhibition of oxidative phosphorylation with the complex I inhibitor rotenone ( Figure 5 ). Since the protection of SCO2 under hypoxia was only partially reverted by inhibition of the respiratory chain, we wondered if SCO2 might protect cells from stress conditions by additional mechanisms. As shown in Supplementary  Figure 3 , SCO2 suppressed intracellular ROS concentrations in LNT-229 and T98G cells both at normoxia and hypoxia. Our results are in agreement with findings in colon carcinoma cells and fibroblasts (Sung et al., 2010) , and suggest that the suppression of ROS could be an additional cytoprotective mechanism of SCO2. How SCO2 suppresses ROS levels in glioma cells is unclear, but might involve reduced intracellular oxygen concentrations (Sung et al., 2010) .
Considering the complex tumor microenvironment, SCO2 might support the viability of tumor cells by Figure 5 A functional respiratory chain is required for the SCO2-mediated protection. (a) LNT-229 p53sh cells ectopically expressing SCO2 (SCO2) or empty pcDNA3 vector-transfected p53sh cells (neo) were exposed to rotenone (100 nM) or vehicle for 24 h, and oxygen consumption was determined (a). In addition, cell death induced by moderate hypoxia (1%) in the absence or presence of rotenone was analyzed in these cells (mean±s.d.). *Po0.05; **Po0.01 (b). T98G cells ectopically expressing SCO2 (SCO2) or empty pcDNA3 vector-transfected T98G cells (neo) and LNT-229 hygro/p53ts cells stably transfected with pcDNA3-SCO2 (SCO2) or a control plasmid (neo) were exposed to serum-free media containing 2 or 25 mM glucose under moderate hypoxia (1% O2) for 24 h, and cell death was assayed by PI-FACS (mean ± s.d.). *Po0.05; **Po0.01 (c). LNT-229 hygro and LNT-229 p53ts cells were exposed to serum-free media containing 2 mM glucose with or without 10 mM methyl-pyruvate under moderate hypoxia (1% O2) for 24 h, and cell death was assayed by PI-FACS (mean±s.d.). *Po0.05; **Po0.01 (d). Here, a representative experiment out of three independent experiments with similar results is shown.
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C Wanka et al increasing energy efficacy in the presence of at least threshold levels of oxygen and thereby reduce glucose consumption. The less efficient glucose metabolism of SCO2-lacking tumor cells could therefore be expected to result in increased necrosis formation. Indeed, the amount of necrosis was significantly increased in SCO2-depleted tumors compared with control tumors (Figure 7) . Similarly, inhibition of monocarboxylate transporter 1 has been shown to result in reduced oxidative phosphorylation and increased glucose consumption of tumor cells near blood vessels, leading to glucose depletion of tumor cells in the tumor core and subsequent extensive necrosis in these areas (Sonveaux et al., 2008) . In summary, this is the first report of SCO2 as a p53-dependent regulator of hypoxia sensitivity in glioma cells. Our results may have important implications for the understanding of the genetic basis of primary glioblastoma and may guide novel approaches towards tumor-selective therapies. Given the fundamental importance of p53 as a tumor suppressor (Efeyan and Serrano, 2007; Kim et al., 2009 ) and the common loss of p53 in secondary glioblastomas Ehrmann et al., 1995) , the absence of p53 mutations in primary glioblastomas and the mutually exclusive occurrence of epidermal growth factor receptor amplification and p53 mutations have long puzzled researchers. The increasingly evident role of hypoxic stress as a key selective pressure for solid tumors (Anderson et al., 2006) has promoted research that aims to elucidate how cancer cells detect and process starvation signals and which pathways mediate adaptive responses that maintain viability (Jiang and Liu, 2008) . Better understanding of these mechanisms may be exploited in several ways: (i) to establish molecular profiles that predict the susceptibility of cancer cells towards hypoxia. This will be of considerable importance, as common clinical interventions modulate tumor hypoxia. Examples include antiangiogenic therapies that increase tumor hypoxia, blood transfusions, erythropoietin application or oxygen delivery that decrease tumor hypoxia (Puduvalli and Sawaya, 2000; Jansen et al., 2004; Rieger et al., 2010) . (ii) Interference with the adaptive responses towards starvation conditions by targeting key regulators of energy metabolism hold great promise as selective antitumor strategies. Specifically, SCO2 is a candidate molecule for this, because its suppression seems to be toxic only under hypoxic conditions. Co-therapy with strategies that target the availability or transport of glucose (Chan et al., 2011) or the activity of glycolytic enzymes may further enhance the impact of suppression of SCO2 on tumor cells, scrambled sh/SCO2 sh cells (b) were seeded into a three-dimensional agar matrix on top of a base agar layer in the presence of 5.5 mM glucose and 3% O 2 . After 4-6 weeks of incubation, colonies were stained by 0.0025% crystal violet and the number of colonies formed in each well was counted. The bars represent the average ± s.d. of three wells counted for each group. The results were confirmed in at least three independent experiments. **Po0.001.
SCO2 inhibits hypoxia-induced cell death C Wanka et al because it will make them more dependent on cellular respiration. Strategies simultaneously targeting oxic and non-oxic metabolic pathways may therefore become an important component of novel antitumor therapies.
Materials and methods
Cell lines
LNT-229 carrying wild-type p53 activity (Lausanne, Switzerland) (Wischhusen et al., 2003) and LN-18 (endogenously mutant p53) cells were kindly provided from N de Tribolet. T98G (endogenously mutant p53) were obtained from ATCC (Rockville, MD, USA). LNT-229 cells expressing a short hairpin construct for the gene suppression of p53 (LNT-229 p53sh) and puro-resistant control cells transfected with the empty vector (LNT-229 puro) (Wischhusen et al., 2003) and LNT-229 cells stably expressing the temperaturesensitive murine p53
V135A
possessing dominant-negative properties at 38.5 1C (LNT-229 p53ts) and hygro-resistant control cells transfected with the empty vector (LNT-229 hygro) have been described (Naumann et al., 1998) . Human HCT116 colon carcinoma cells carrying wild-type p53 (p53 þ / þ ) and HCT116 cells with a targeted deletion of p53 (p53
) were provided by B Vogelstein (Bunz et al., 1998) . SCO2 shRNA in pLKO.1 was stably transduced into HCT116 p53
þ / þ -SCO2 sh) and selected with puro for 10 days. A scrambled shRNA in pLKO.1 was used as control (HCT116 p53 þ / þ -scrambled sh). Gene expression was confirmed by RT-PCR. The glioma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (PAA, Coelbe, Germany) containing 10% fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin. LNT-229 hygro, LNT-229 p53ts cells and transfectants derived from those cells were cultivated at 38.5 1C. In experiments requiring defined glucose concentrations, glucose as required was added to DMEM glucose free medium (PAA). Cells were seeded at a density of 5.7 Â 10 4 cells per cm 2 , if not otherwise specified.
Constructs
Gene suppression of p53 was accomplished with the pSUPERpurop53shRNA vector (Wischhusen et al., 2003) . The hygro control vector and the p53 V135A construct were a gift from M Clarke. The p53-luc reporter gene vector PathDetect p53 was purchased from Stratagene (Cedar Creek, TX, USA), pRL-CMV Renilla vector was from Promega (Mannheim, Germany). pcDNA3.1-SCO2 was generously provided by P Hwang (Matoba et al., 2006) . The control pcDNA3.1 vector was purchased from Invitrogen (Karlsruhe, Germany). Stable and transient transfections of plasmids were achieved using Metafectene pro (Biontex, Martinsried/Planegg, Germany) for LNT-229 or T98G cells. For stable knockdown of human SCO2 expression, five different SCO2 shRNA (Sigma Aldrich, Taufkirchen, Germany) were each stably transduced into HCT116 p53
þ / þ cells via a pLKO.1-based lentiviral system. The envelope plasmid 8454 pCMV-VSV-G and packaging plasmid 8455 pCMV-dR8.2 dvpr were purchased from Addgene (Cambridge, MA, USA). The protocol was adapted according to a previous report (Stewart et al., 2003) . Experiments were carried out with the most effective SCO2 shRNA sequence (Sigma Aldrich; TRCN0000236560, 5 0 -CCGGAGTTACCGCGTGTACTACAATCTCGAGATTG TAGTACACGCGGTAACTTTTTTG-3 0 ). A scrambled shRNA in pLKO.1 was used as control. For transient gene suppression of human SCO2, a predesigned siRNA was 
Induction of hypoxia
Profound hypoxia (0.1% O 2 ) was induced by incubating cells in Gas Pak pouches for anaerobic culture (Becton-Dickinson, Heidelberg, Germany) (Steinbach et al., 2003) . Moderate hypoxia (1% O 2 ) was induced in a Labotect incubator (Goettingen, Germany). Briefly, cells were seeded and allowed to attach in the medium containing 10% fetal calf serum for 24 h. The medium was removed and the cells were incubated in serum-free DMEM adjusted to 2 mM glucose under normoxia (21% O 2 ), moderate (1% O 2 ) or profound hypoxia (0.1% O 2 ) for the indicated periods of time.
Immunoblot analysis Cells were seeded in six-well plates and exposed to serum-free medium containing 2 mM glucose in the presence of 21, 1 or 0.1% O 2 for 20 h as indicated. Thereafter, cells were washed with cold phosphate-buffered saline and lysed in lysis buffer (50 mM Tris-HCl (pH 8), 120 mM NaCl, 5 mM EDTA, 0.5% NP-40) containing protease inhibitors (Roche, Mannheim, Germany). Cellular lysates were prepared as described (Steinbach et al., 2003) and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Membranes were probed with antibodies to human p53 (sc-263; Santa Cruz, San Diego, CA, USA), murine p53 (p53-Ab-4; Merck, Darmstadt, Germany), GAPDH (MAB374; Chemicon, Nuernberg, Germany), AMPKa (2531; Cell Signaling, Frankfurt am Main, Germany), phospho-AMPKa (2531; Cell Signaling), acetyl coA carboxylase (3662; Cell Signaling), phospho-acetyl coA carboxylase (3661; Cell Signaling), actin (SC1616; Santa Cruz) or phospho-4E binding protein 1 (9459; Cell Signaling). Secondary antibodies were purchased from Santa Cruz. The chemiluminescence solution used for detection was composed of 1 ml solution A (200 ml 0.1 M Tris-HCl pH 8.6, 50 mg Luminol), 100 ml solution B (11 mg phospho-hydroxycourmarin acid, 10 ml dimethyl sulfoxide) and 0.3 ml H 2 O 2 (30%).
Luciferase assay
Cells were seeded at 10 000 cells per well into 96-well plates, co-transfected using Metafectene pro (Biontex) with the p53-luc reporter gene vector and pRL-CMV (Renilla) vector (Promega) at a ratio of 7.5:1, and exposed to 2 mM glucose and oxygen concentrations for 16 h. Experiments were conducted in triplicates. Activities of luciferase and firefly were determined using a luminometer (Mithras, Berthold Technologies, Bad Wildbad, Germany). Background was subtracted from all values and the counts obtained from the measurement of firefly luciferase were normalized to Renilla luciferase (Dyer et al., 2000; Wischhusen et al., 2004) .
Cell death analysis
Cells were seeded in 24-well plates at 50 000 per cm 2 . After 24 h, the medium was removed and cells were incubated in DMEM containing 2 mM glucose in the presence of 21, 1 or 0.1% O 2 for 20 h. Thereafter, adherent and non-adherent cells were collected, washed in phosphate-buffered saline, stained with 1 mg/ml PI and analyzed by flow cytometry in a BD Canto II (BD, Heidelberg, Germany). PI-positive cells were regarded as dead cells, and the percentage of dead cells in relation to all analyzed cells was determined. Experiments were performed in triplicates and are presented as mean±s.d. Selected results were replicated by LDH assay (Roche) according to the manufacturer's instructions.
ROS analysis
Cells were seeded in 24-well plates. After 24 h, the medium was removed, and cells were incubated in DMEM containing 5 mM glucose in the presence of 21 or 1% O 2 for 20 h. Cells were then In the presence of wild-type p53, starvation signals induce p53 via the AMPK sensor system. P53 suppresses glycolysis and induces SCO2, which promotes oxidative phosphorylation in the mitochondria. Under the conditions of the tumor microenvironment characterized by hypoxia and low glucose availability, increased efficacy of ATP production in the mitochondria serves to maintain energy homeostasis and viability. Furthermore, expression of SCO2 limits ROS levels. (b) Inactivation of p53 or suppression of SCO2 deregulates glycolysis and impairs mitochondrial respiration, leading to increased glucose consumption, while the amount of ATP generated per mol glucose is decreased. Under starvation conditions, these metabolic alterations induce rapid energy depletion and subsequent cell death. Reduced expression of SCO2 results in increased intracellular ROS levels, which may further contribute to cell death.
SCO2 inhibits hypoxia-induced cell death C Wanka et al washed twice with phosphate-buffered saline, incubated 20 min, 37 1C with 10mM H 2 DCFDA (Invitrogen), washed with phosphate-buffered saline and collected for flow cytometry analysis. DCF signal was analyzed by BD Canto II. Experiments were performed in triplicates and are presented as mean±s.d.
Measurement of glucose and lactate
Cell-free supernatant was collected and glucose and lactate concentrations were measured using the biochemistry analyzer Hitachi 917.
RNA extraction and qRT-PCR analysis
Total RNA was extracted using Trizol and RNAeasy Kit (Invitrogen). First-strand cDNA was synthesized using the Vilo cDNA synthesis kit (Invitrogen) for 10 min at 25 1C and 2 h at 42 1C. Subsequently, the enzyme was inactivated at 85 1C for 10 min. To determine changes in gene expression, qRT-PCR was performed in the IQ5 real-time PCR detection system (Biorad, Muenchen, Germany) using Absolute Blue Q-PCR Mastermix with SybrGreen þ Fluorescein (Thermo Fisher Scientific, Hamburg, Germany) and the following primer pairs: SCO2 fw, 5 0 -CTTCACTCACTGCCCTGACA-3 0 , SCO2, bw 5 0 -TGAGCAGGTAGATGGCAATG-3 0 ; 18S fw, 5 0 -CGGCT ACCACATCCAAGGAA-3 0 , 18S bw, 5 0 -GCTGGAATTACC GCGGCT-3 0 . Cycle threshold (C t ) values were normalized for amplification of the 18S ribosomal RNA and the data were analyzed according to Vandesompele et al. (2002) .
Oxygen consumption A total of 250 000 cells were seeded in 3 cm diameter glass dishes. After 24 h, cells were treated with the medium preincubated at the required temperature (37 or 38.5 1C), the lids were sealed using rubber gaskets and the dishes were tightly closed by two cramps. Oxygen concentration in the medium was measured using the ABL-80 FLEX Blood Gas Analyzer (Radiometer, Willich, Germany) before and after incubation for 48 h. Oxygen consumption was normalized for protein concentration.
ATP assay
Immediately after hypoxic incubation, the plates were placed on ice and the cells were pelleted by centrifugation and lysed in ATP releasing reagent (Sigma, Steinheim, Germany). The ATP concentration was determined by luciferase assay with the CLS II kit (Boehringer, Mannheim, Germany) (Steinbach et al., 2003) .
Anchorage-independent growth (soft agar colony assay) Cells were suspended in 0.35% agar medium (DMEM containing 5.5 mM glucose, 10% fetal calf serum, 2 mM GlutaMAX-I Supplement (Invitrogen)) at a concentration of 5 Â 10 3 cells per 6-cm dish, and then plated on a 0.5% agar base layer (also containing 5.5 mM glucose, 10% fetal calf serum and 2 mM GlutaMAX-I Supplement). GlutaMAX contains L-alanyl-L-glutamine, a stabilized form of L-glutamine, preventing degradation and ammonia build-up during long-term cultures. Cells were then incubated in a humidified atmosphere (5% CO 2 ) at 37 1C. At 24 h after seeding, 2 ml of the medium was added on the top agar and cells were incubated at 3% O 2 for at least 4 weeks. Colonies were stained by 0.0025% crystal violet for 4 h and counted thereafter.
In vivo assays
In total, 4 Â 10 6 HCT116 p53 þ / þ and p53 À/À cells and 2 Â 10
